Hjem › Adenokarcinom i spiserøret › Virginia
Kliniske studier for Adenokarcinom i spiserøret i Virginia
13 studier for Adenokarcinom i spiserøret søker deltakere på steder i Virginia.
Byer i Virginia
Offisiell studietekst (engelsk)
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- og 6 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05677490A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Oncology and Hematology Associates of Southwest Virginia, Inc. - Salem, Salem
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07221149Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Inova Schar Cancer Institute, Fairfax
- Virginia Cancer Specialists, PC, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06324357Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Virginia Cancer Specialists, PC, Arlington
- Virginia Oncology Associates, Chesapeake
- Virginia Cancer Specialists, PC, Fairfax
- og 7 flere
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07392892A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- NEXT Oncology Virginia, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07277413Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Blacksburg
- Research Site, Fairfax
- Research Site, Fort Belvoir
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07182149A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Virginia Cancer Specialists, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06330064A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Virginia Cancer Specialists, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT06657144A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Virginia Cancer Specialists, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT04389632First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Research Site, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jun. 2026 · NCT07284186A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- NEXT Virginia, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 8. mai 2026 · NCT05954312Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.